Shares of Genocea Biosciences Inc (NASDAQ:GNCA) have received a consensus rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $4.00.
A number of brokerages have issued reports on GNCA. HC Wainwright set a $5.00 target price on Genocea Biosciences and gave the company a “buy” rating in a research report on Thursday, August 2nd. Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Monday, November 5th.
Genocea Biosciences stock traded down $0.04 during midday trading on Friday, hitting $0.62. 600 shares of the company were exchanged, compared to its average volume of 209,301. The firm has a market capitalization of $57.29 million, a PE ratio of -0.32 and a beta of 1.14. The company has a debt-to-equity ratio of 1.91, a quick ratio of 4.01 and a current ratio of 4.01. Genocea Biosciences has a fifty-two week low of $0.49 and a fifty-two week high of $1.39.
Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. On average, analysts forecast that Genocea Biosciences will post -0.45 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System raised its position in shares of Genocea Biosciences by 166.6% during the 1st quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 78,469 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Genocea Biosciences by 71.1% during the 3rd quarter. Renaissance Technologies LLC now owns 198,766 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 82,600 shares in the last quarter. LMR Partners LLP acquired a new stake in shares of Genocea Biosciences during the 2nd quarter valued at approximately $175,000. DRW Securities LLC acquired a new stake in shares of Genocea Biosciences during the 2nd quarter valued at approximately $205,000. Finally, Fosun International Ltd acquired a new stake in shares of Genocea Biosciences during the 3rd quarter valued at approximately $323,000. 60.86% of the stock is currently owned by institutional investors.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Further Reading: Treasury Bonds
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.